Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationKnowledge · learning hub
Patient Resources
A calm place to understand what is happening, written to reduce fear with understanding.
A calm place to understand things
Reduce fear with understanding. Never alarm.
Four pillars: the Cancer Dictionary, the Biomarker Library, the Video Library and the FAQ. The first two have grown into sections of their own.
Plain language
Written for a sixth-grade reading level, without dumbing down.
No frightening statistics
We avoid numbers presented without context.
Always a next step
Every article ends with somewhere useful to go.
Now a section of its own
Cancer Dictionary
One structured entry per cancer type, each answering the same eight questions in the same order.
The dictionary has outgrown this page. It now holds a full entry for each of 37 cancer types: the governing idea, the major disease categories, what is discussed molecularly, when that information matters across the course of the disease, and the questions worth raising with a treating team.
Open the Cancer DictionaryBiomarker Library
The general terms, in one place
These come up in almost every entry, so they are collected here rather than repeated. Each dictionary entry also carries its own glossary for terms specific to that cancer.
- Biomarker
- A measurable feature of a cancer, often a gene change, that guides treatment choice.
- ctDNA
- Tumour DNA fragments shed into the blood, readable by a liquid biopsy.
- Germline
- Genetic changes you are born with and can pass on. The focus of Heritage.
- MRD
- Molecular residual disease. Microscopic cancer left after treatment, found by Clear.
- MSI
- A sign the tumour’s DNA repair is faulty. Often predicts immunotherapy response.
- Somatic
- Changes a tumour acquires during life. Not inherited.
- TMB
- Tumour mutational burden. How many mutations a tumour carries.
- Targeted therapy
- A drug aimed at a specific molecular change driving the cancer.
Also a section of its own
Biomarker Library
One page-length entry per marker: what it actually is, why it gets discussed, how it is measured, and what a result does not tell you.
Markers are the part of a report people most often try to look up and most often misread, because the same marker can mean different things in different cancers and be measured by methods that are not interchangeable. The library says so, marker by marker, and links each one to the cancers where it comes up.
| Marker | Why people look it up |
|---|---|
| EGFR | A common driver in lung cancer, with several generations of matched therapy. |
| ALK, ROS1, RET, NTRK | Fusion drivers. A panel that reads only point mutations will miss them. |
| KRAS | The most frequent driver in several cancers. The specific variant matters. |
| BRAF | V600E specifically. Non-V600E variants do not carry the same evidence. |
| HER2 (ERBB2) | Amplification and mutation are two different findings. |
| BRCA1 and BRCA2 | Relevant both as a tumour finding and as inherited risk. Not the same test. |
| MMR and MSI | One of the clearest tumour-agnostic markers, and the main route to finding Lynch syndrome. |
| TMB | Panel size and method both change the number, so values are not comparable across assays. |
| ctDNA | A “not detected” result may mean the tumour sheds little DNA, not that it is absent. |
Also available in your language
Every article and video is translated into regional languages, because understanding your own diagnosis should not depend on reading technical English.
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal